Company Profile

Marksans Pharma has completed the acquisition of a manufacturing site from Tevapharm India. The acquisition was first announced in October 2022. With the completion of the acquisition, Marksans will start operating at the acquired facility. As a part of the agreement, Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards. The contract manufacturing agreement with Teva is to continue providing an uninterrupted supply of Teva's important medicines to customers and patients. Marksans has retained the transferring employees on terms materially similar to its current employment. Teva's adjoining Watson Pharma’s site is not part of the divestment with Marksans and will remain with Teva.

The acquired facility will enable Marksans Pharma to potentially double the existing Indian capacity from 8bn units per annum currently. It is a scalable capacity to manufacture oral solid dosage forms. Marksans plans to manufacture tablets, hard and soft gel capsules, ointments, liquids, and creams, from the new capacity. The manufacturing site is spread across 47,597 square meters and has approvals to manufacture products from the EU, Health Canada & Japanese Health Authority.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma is currently trading at Rs. 77.27, up by 1.13 points or 1.48% from its previous closing of Rs. 76.14 on the BSE.

The scrip opened at Rs. 75.56 and has touched a high and low of Rs. 78.37 and Rs. 75.50 respectively. So far 191349 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 79.10 on 17-Apr-2023 and a 52 week low of Rs. 38.70 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 79.10 and Rs. 71.50 respectively. The current market cap of the company is Rs. 3507.49 crore.

The promoters holding in the company stood at 49.00%, while Institutions and Non-Institutions held 5.20% and 45.80% respectively.
 
Marksans Pharma has completed the acquisition of a manufacturing site from Tevapharm India. The acquisition was first announced in October 2022. With the completion of the acquisition, Marksans will start operating at the acquired facility. As a part of the agreement, Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards. The contract manufacturing agreement with Teva is to continue providing an uninterrupted supply of Teva's important medicines to customers and patients. Marksans has retained the transferring employees on terms materially similar to its current employment. Teva's adjoining Watson Pharma’s site is not part of the divestment with Marksans and will remain with Teva.

The acquired facility will enable Marksans Pharma to potentially double the existing Indian capacity from 8bn units per annum currently. It is a scalable capacity to manufacture oral solid dosage forms. Marksans plans to manufacture tablets, hard and soft gel capsules, ointments, liquids, and creams, from the new capacity. The manufacturing site is spread across 47,597 square meters and has approvals to manufacture products from the EU, Health Canada & Japanese Health Authority.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sandra Saldanha & PACs.

The above information is a part of company’s filings submitted to BSE.